Innova Biosciences Awarded EU Grant to Develop Cancer Biomarker Discovery Platform
News Feb 18, 2009
Innova Biosciences Ltd has been awarded €455,000 of a €3,000,000 European grant. Through the PROACTIVE consortium along with Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University, and Integromics S.L., a high throughput plasma screening platform will be developed for the discovery of biomarkers of early stage cancer.
Innova Biosciences has had enormous success with its range of Lightning-Link™ bioconjugation products, which provide a simple method for joining biomolecules, a process carried out in thousands of research laboratories worldwide.
Innova Biosciences’ participation in the PROACTIVE consortium to develop immunodiagnostics reagents will help cement the company’s position as a world leader in bioconjugation technology.
Commenting on the EU grant Dr Nick Gee, CEO of Innova Biosciences said “We are delighted to be granted such a prestigious award which recognizes Innova’s proprietary knowledge and expertise. Participating in the development of a new immunodiagnostic platform that will facilitate early stage cancer detection is an exciting application of our technology, which will directly benefit human health.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.